{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:17:26Z","timestamp":1777393046037,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is of growing concern worldwide as the demographic changes to a more aged population. Amyloid-\u03b2 (A\u03b2 deposition is thought to be a key target for treating AD. However, A\u03b2 antibodies have had mixed results, and there is concern over their safety. Studies have shown that the sigma-2 receptor (\u03c3-2R)\/TMEM97 is a binding site for A\u03b2 oligomers. Therefore, targeting the receptor may be beneficial in displacing A\u03b2 oligomers from the brain. CT1812 is a \u03c3-2R\/TMEM97 antagonist that is effective in preclinical studies of AD and has been entered into clinical trials. Objective: The objective of this study was to systematically review the safety and efficacy of CT1812 for the treatment of AD. Methods: Between June and August 2023, we searched the primary literature (PubMed, Scopus, Google Scholar, etc.) and clinical trials databases (http:\/\/www.clinicaltrails.gov). The extracted data is evaluated within this manuscript. Results: CT1812 is relatively safe, with only mild adverse events reported at doses up to 840\u200amg. CT1812 can displace A\u03b2 in the clinical studies, in line with the preclinical data. Studies have investigated brain connectivity and function in response to CT1812. However, the cognitive data is still lacking, with only one study including cognitive data as a secondary outcome. Conclusions: CT1812 safely works to displace A\u03b2 however, whether this is enough to prevent\/slow the cognitive decline seen in AD remains to be seen. Longer clinical trials are needed to assess the efficacy of CT1812; several trials of this nature are currently ongoing.<\/jats:p>","DOI":"10.3233\/jad-230994","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T10:51:22Z","timestamp":1729248682000},"page":"S115-S128","source":"Crossref","is-referenced-by-count":3,"title":["CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer\u2019s Disease Treatment: A Systematic Review of Available Clinical Data"],"prefix":"10.1177","volume":"101","author":[{"given":"Premrutai","family":"Thitilertdecha","sequence":"first","affiliation":[{"name":"Siriraj Research Group in Immunobiology and Therapeutic Sciences, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Michael","family":"Brimson","sequence":"additional","affiliation":[{"name":"Research Unit for Innovation and International Affairs, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230994_ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease","volume":"41","author":"G\u00f3mez-Isla","year":"1997","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230994_ref2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00429-007-0153-1","article-title":"Mitochondrial degeneration in dystrophic neurites of senile plaques may lead to extracellular deposition of fine filaments","volume":"212","author":"Fiala","year":"2007","journal-title":"Brain Struct Funct"},{"key":"10.3233\/JAD-230994_ref3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","article-title":"Systemic inflammation and disease progression in Alzheimer disease","volume":"73","author":"Holmes","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-230994_ref4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-022-00589-x","article-title":"Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes","volume":"17","author":"Kim","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-230994_ref5","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","article-title":"Synaptic targeting by Alzheimer\u2019s-related amyloid beta oligomers","volume":"24","author":"Lacor","year":"2004","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-230994_ref6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tips.2013.03.002","article-title":"The case for soluble A\u03b2 oligomers as a drug target in Alzheimer\u2019s disease","volume":"34","author":"Hefti","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-230994_ref7","first-page":"197","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230994_ref8","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.3233\/JAD-230994_ref9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of aducanumab in the treatment of Alzheimer\u2019s disease: Challenges and opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-230994_ref10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/psyg.12944","article-title":"Aducanumab for the treatment of Alzheimer\u2019s disease: A systematic review","volume":"23","author":"Rahman","year":"2023","journal-title":"Psychogeriatrics"},{"key":"10.3233\/JAD-230994_ref11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230994_ref12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230994_ref13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230994_ref14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230994_ref15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-230994_ref16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: A randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230994_ref17","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: Results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.3233\/JAD-230994_ref18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.3233\/JAD-230994_ref19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40263-023-01007-6","article-title":"Targeting Sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders","volume":"37","author":"Malar","year":"2023","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-230994_ref20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14728222.2020.1805435","article-title":"Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain","volume":"24","author":"Brimson","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.3233\/JAD-230994_ref21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14728222.2021.1939681","article-title":"The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer\u2019s disease","volume":"25","author":"Prasanth","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.3233\/JAD-230994_ref22","doi-asserted-by":"crossref","first-page":"e111899","DOI":"10.1371\/journal.pone.0111899","article-title":"Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JAD-230994_ref23","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.1705154114","article-title":"Identification of the gene that codes for the \u03c3(2) receptor","volume":"114","author":"Alon","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-230994_ref24","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1021\/acschemneuro.7b00200","article-title":"Sigma 2 receptor\/Tmem97 agonists produce long lasting antineuropathic pain effects in mice","volume":"8","author":"Sahn","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-230994_ref25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1208\/s12248-020-00472-x","article-title":"Discovery of a highly selective sigma-2 receptor ligand, 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with drug-like properties and antinociceptive effects In Vivo","volume":"22","author":"Intagliata","year":"2020","journal-title":"AAPS J"},{"key":"10.3233\/JAD-230994_ref26","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acschemneuro.8b00543","article-title":"Neuroprotective efficacy of a sigma 2 receptor\/TMEM97 modulator (DKR-1677) after traumatic brain injury","volume":"10","author":"V\u00e1zquez-Rosa","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"10.3233\/JAD-230994_ref27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/ncomms1386","article-title":"Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site","volume":"2","author":"Xu","year":"2011","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-230994_ref28","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/bjc.2013.593","article-title":"Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer","volume":"109","author":"Zeng","year":"2013","journal-title":"Br J Cancer"},{"key":"10.3233\/JAD-230994_ref29","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.ebiom.2015.10.017","article-title":"The Sigma-2 receptor and progesterone receptor membrane component 1 are different binding sites derived from independent genes","volume":"2","author":"Chu","year":"2015","journal-title":"EBioMedicine"},{"key":"10.3233\/JAD-230994_ref30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/bjc.2011.602","article-title":"Sigma-2 ligands induce tumour cell death by multiple signalling pathways","volume":"106","author":"Zeng","year":"2012","journal-title":"Br J Cancer"},{"key":"10.3233\/JAD-230994_ref31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/17425255.2012.658367","article-title":"S2RPgrmc1: The cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling","volume":"8","author":"Ahmed","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.3233\/JAD-230994_ref32","doi-asserted-by":"publisher","DOI":"10.4172\/2329-6488.1000e130"},{"key":"10.3233\/JAD-230994_ref33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.phrs.2016.12.023","article-title":"Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1","volume":"117","author":"Pati","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.3233\/JAD-230994_ref34","doi-asserted-by":"crossref","first-page":"16845","DOI":"10.1038\/s41598-018-35430-3","article-title":"Sigma-2 receptor\/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex","volume":"8","author":"Riad","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-230994_ref35","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s12035-020-01988-1","article-title":"The sigma-2 receptor\/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of A\u03b2 42 and its protein aggregates","volume":"57","author":"Riad","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-230994_ref36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/jnc.13917","article-title":"Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer\u2019s disease","volume":"140","author":"Yi","year":"2017","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-230994_ref37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/acsmedchemlett.1c00002","article-title":"Sigma-1 and sigma-2 receptor modulators as potential therapeutics for Alzheimer\u2019s disease","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.3233\/JAD-230994_ref38","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.3390\/molecules25225439","article-title":"Sigma-2 receptor-A potential target for cancer\/Alzheimer\u2019s disease treatment via its regulation of cholesterol homeostasis","volume":"25","author":"Yang","year":"2020","journal-title":"Molecules"},{"key":"10.3233\/JAD-230994_ref39","doi-asserted-by":"crossref","first-page":"e111898","DOI":"10.1371\/journal.pone.0111898","article-title":"Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JAD-230994_ref40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230994_ref41","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer\u2019s disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.3233\/JAD-230994_ref42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A Phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-230994_ref43","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41598-020-80045-2","article-title":"The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: Analysis of the available clinical data","volume":"11","author":"Brimson","year":"2021","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-230994_ref44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JAD-230994_ref45","doi-asserted-by":"crossref","first-page":"P1183","DOI":"10.1016\/j.jalz.2016.07.127","article-title":"P4-381: A two-part, double-blind, placebo-controlled, Phase 1 study of the safety and pharmacokinetics of single and multiple ascending doses of CT1812 in healthy volunteers.","volume":"12","author":"Catalano","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230994_ref47","doi-asserted-by":"crossref","first-page":"P1570","DOI":"10.1016\/j.jalz.2017.07.730","article-title":"[P4\u2013567]: A Phase 1 safety trial of the A\u03b2 oligomer receptor antagonist CT1812","volume":"13","author":"Catalano","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230994_ref48","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.3390\/ijms221910889","article-title":"Electroencephalography as a non-invasive biomarker of Alzheimer\u2019s disease: A forgotten candidate to substitute CSF molecules?","volume":"22","author":"Monllor","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.3233\/JAD-230994_ref49","doi-asserted-by":"crossref","first-page":"e0231169","DOI":"10.1371\/journal.pone.0231169","article-title":"Quantile graphs for EEG-based diagnosis of Alzheimer\u2019s disease","volume":"15","author":"Pineda","year":"2020","journal-title":"PLoS One"},{"key":"10.3233\/JAD-230994_ref50","first-page":"135","article-title":"Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease","volume":"2","author":"Morris","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-230994_ref51","doi-asserted-by":"crossref","first-page":"e154889","DOI":"10.1172\/JCI154889","article-title":"Aducanumab for Alzheimer disease: The amyloid hypothesis moves from bench to bedside","volume":"131","author":"Musiek","year":"2021","journal-title":"J Clin Invest"},{"key":"10.3233\/JAD-230994_ref52","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"10.3233\/JAD-230994_ref53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.3233\/JAD-230994_ref54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-230994_ref55","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab \u2014 binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-230994_ref56","doi-asserted-by":"crossref","first-page":"108342","DOI":"10.1016\/j.neuropharm.2020.108342","article-title":"Sigma ligands as potent inhibitors of A\u03b2 and A\u03b2 Os in neurons and promising therapeutic agents of Alzheimer\u2019s disease","volume":"190","author":"Ma","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-230994_ref57","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.2174\/0929867327666200902172615","article-title":"Sigma-2 receptor as a potential drug target","volume":"28","author":"Chen","year":"2021","journal-title":"Curr Med Chem"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:59:14Z","timestamp":1777370354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/JAD-230994"}},"subtitle":[],"editor":[{"given":"Paula I.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Jesus","family":"Avila","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Daniela","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Aaron A.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":56,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-230994","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}